Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19989672 | 0.95 | MMP2 (0.35) | MMP2MMP3SIGMAR1CACNA1GKCNH2 | |
| SCHEMBL23735021 | 0.92 | SIGMAR1 (0.35) | MMP2MMP3SIGMAR1CACNA1GKCNH2 | |
| SCHEMBL20001502 | 0.91 | MMP2 (0.40) | MMP2MMP3 | |
| SCHEMBL19989641 | 0.88 | SIGMAR1 (0.36) | MMP2MMP3SIGMAR1CACNA1GKCNH2 | |
| SCHEMBL19989622 | 0.88 | DRD3 (0.42) | CACNA1GKCNH2KDM4EDRD3HTR1A | |
| SCHEMBL19989574 | 0.87 | MMP2 (0.37) | MMP2MMP3SIGMAR1KDM4EDRD2 | |
| SCHEMBL20001507 | 0.86 | MMP2 (0.41) | MMP2MMP3 | |
| SCHEMBL19989579 | 0.86 | MMP2 (0.38) | MMP2MMP3 | |
| SCHEMBL19989590 | 0.86 | DRD2 (0.41) | CACNA1GKCNH2KDM4EDRD3DRD2 | |
| SCHEMBL20025547 | 0.84 | DRD2 (0.38) | SIGMAR1DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086709-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | DONG-A ST CO., LTD. (KR) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086709-A1 | TETRAHYDROPYRIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | GALE, UGDH, PGLS | MMP2 314/4885MMP3 358/4885SIGMAR1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.